You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Antibiotic susceptibility and clinical outcomes in a study of 60 patients with blood culture-proven typhoid fever

From: Clinical outcomes in typhoid fever: adverse impact of infection with nalidixic acid-resistant Salmonella typhi

Variable All patients (n = 60) NARST (n = 47) NASST (n = 13) MDR-ST (n = 22) NonMDR-ST (n = 38)
MIC ciprofloxacin, μg/mL 0.33 ± 0.21 0.37 ± 0.21* 0.17 ± 0.14* 0.37 ± 0.26 0.30 ± 0.18
MIC ceftriaxone, μg/mL 0.036 ± 0.016 0.038 ± 0.018 0.031 ± 0.01 0.033 ± 0.017 0.039 ± 0.016
Fever clearance time, days 5.1 ± 3.5 5.5 ± 3.8 3.7 ± 1.3 4.9 ± 2.7 5.3 ± 3.9
Total duration of illness, days 14.3(9.8–21) 16.3(11.4–24)* 9.6(6.8–10)* 14.5(9.3–21.4) 14.3(9.9–22)
Complications 11 (18) 11 (23) -- 2 (9) 9 (24)
  1. NARST = nalidixic acid-resistant Salmonella typhi
  2. NASST = nalidixic acid-sensitive Salmonella typhi
  3. MDR-ST = multidrug-resistant Salmonella typhi
  4. MIC = minimum inhibitory concentration
  5. -- no patients in this category
  6. * P-value < 0.05 for NARST vs. NASST; compared by independent t test or Mann-Whitney U test
  7. includes encephalopathy, hepatitis, lower gastrointestinal bleeding, meningitis and myocarditis. Presented as number (%) of patients; all other data given as mean ± SD or median (IQR)